Efficacy of Topical Nepafenac 0.3% in the Management of Postoperative Cystoid Macular Edema

Abstract

Athanassios K Giarmoukakis,* Styliani V Blazaki,* Georgios C Bontzos, Argyro D Plaka, Konstantinos N Seliniotakis, Larissa D Ioannidi, Miltiadis K Tsilimbaris Department of Ophthalmology, University Hospital of Heraklion, Heraklion, Greece*These authors contributed equally to this workCorrespondence: Miltiadis K TsilimbarisUniversity Hospital of Heraklion, Heraklion 71003, Crete, GreeceTel [phone]Fax [phone]Email [email protected]: To assess the effect of twice-daily nepafenac ophthalmic suspension 0.3% on postoperative cystoid-macular-edema (CME).Patients and Methods: In this prospective, clinic-based, non-randomized case-series, 21 patients (21 eyes) were enrolled with either acute or chronic postoperative CME after cataract extraction. Patients were treated with twice-daily nepafenac 0.3% drops, and followed for at least a 4-month period. Best-corrected visual acuity (BCVA) and spectral-domain optical coherence tomography (SD-OCT)-derived central retinal thickness (CRT) were measured.Results: From 21 patients, eight presented with acute postoperative CME and 13 with chronic CME. Mean follow-up was 4.82± 1.24 months. No adverse events were reported during the study. Baseline BCVA was 0.49± 0.36 logMAR and improved to 0.36± 0.42 logMAR at the last follow-up visit (P< 0.005). CRT decreased from 450.40± 90.74 μm at baseline to 354.60± 81.49 μm (P< 0.05), following treatment.Conclusion: Our outcomes strongly suggest that administrating nepafenac 0.3% drops on a twice-daily regimen could be a promising alternative for the management of postoperative CME. Additional studies are necessary to further validate our results.Keywords: nepafenac, postoperative macular edema, cataract operation, topical use, treatment

Keywords

• nepafenac
• postoperative macular edema
• cataract operation
• topical use
• treatment